Form 4: BioCardia CEO Boosts Stake with 48K Shares & Warrants
Insider Transaction Report
BioCardia's President and CEO, Peter Altman, acquired 48,000 shares of common stock and an equal number of warrants in a public offering on September 19, 2025.
Summary
- Peter Altman, President and CEO, and a Director of BioCardia, Inc. (BCDA), purchased securities in a public offering.
- On September 19, 2025, Altman acquired 48,000 shares of BioCardia Common Stock at a price of $1.25 per share.
- Concurrently, Altman also received 48,000 warrants, each exercisable to purchase one share of common stock at $1.25, expiring on September 20, 2027.
- Following these transactions, Altman directly beneficially owns 216,762 shares of Common Stock and 143,612 warrants.
- The acquisition was part of a public offering where one share of common stock and one warrant were received for each share purchased.
Sentiment
Score: 8
Explanation: The sentiment is highly positive due to the significant insider buying by the President and CEO, indicating strong confidence in the company's future prospects.
Positives
- The President and CEO's direct purchase of a significant number of shares and warrants signals strong confidence in the company's future prospects and valuation.
- Insider buying, especially from top management, often indicates a belief that the stock is undervalued or that positive developments are anticipated.
Future Outlook
The filing does not contain explicit forward-looking statements or guidance, but the insider purchase itself can be interpreted as a positive outlook from management.
Management Comments
- The direct purchase of shares and warrants by President and CEO Peter Altman reflects a strong vote of confidence in BioCardia's strategic direction and future value.
Industry Context
Insider buying, particularly by a CEO, is generally viewed as a positive signal in the biotechnology and medical device industry, suggesting management believes in the company's pipeline, market position, or upcoming catalysts. Such actions can differentiate a company from competitors by demonstrating strong internal conviction.
Related Party Transactions
- Peter Altman, as President, CEO, and Director, purchased shares and warrants directly from BioCardia, Inc. (the Issuer) in a public offering, which constitutes a related party transaction.
Stakeholder Impact
- Shareholders may view the CEO's purchase as a positive signal, potentially increasing investor confidence and demand for the stock.
- The public offering itself, while providing capital to the company, may have resulted in some dilution for existing shareholders.
Key Dates
| Date | Description |
|---|---|
| 09/19/2025 | Date of transaction for the acquisition of common stock and warrants in a public offering. |
| 09/23/2025 | Date the Form 4 was signed and filed. |
| 09/20/2027 | Expiration date for the warrants acquired. |
Recommendation
buyThe significant purchase of common stock and warrants by BioCardia's President and CEO, Peter Altman, in a public offering is a strong signal of insider confidence. This direct investment suggests management believes the company's shares are undervalued or anticipates positive future developments, making it a compelling 'buy' signal for investors.
Keywords
BioCardia, BCDA, Peter Altman, Insider Trading, Stock Purchase, Warrants, Public Offering, CEO, Director, Equity Acquisition
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.